United Therapeutics Corporation
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $1.56B | $1.70B | $1.21B | $961.2M | $894.8M | $738.7M | $738.4M | $669.2M |
| Accounts Receivable | $350.2M | $279.3M | $278.9M | $220.4M | $198.7M | $157.4M | $151.4M | $175.7M |
| Inventory | $183.1M | $157.9M | $111.8M | $102.0M | $93.8M | $86.5M | $93.4M | $101.0M |
| Total Current Assets | $3.70B | $3.87B | $3.55B | $3.38B | $2.32B | $2.17B | $1.86B | $1.77B |
| Property, Plant & Equipment | $1.73B | $1.22B | $1.05B | $861.5M | $780.9M | $731.6M | $738.5M | $699.7M |
| Goodwill | $32.3M | $32.3M | $33.7M | $28.0M | $28.0M | $28.0M | $28.0M | $31.5M |
| Intangible Assets (Excl. Goodwill) | — | — | — | — | — | — | — | — |
| Total Assets | $7.88B | $7.36B | $7.17B | $6.04B | $5.17B | $4.62B | $3.91B | $3.40B |
| Liabilities | ||||||||
| Accounts Payable | $7.1M | $6.0M | $5.6M | $4.1M | $3.8M | $4.1M | $9.9M | $23.1M |
| Total Current Liabilities | $560.6M | $738.1M | $804.4M | $343.2M | $305.4M | $323.3M | $463.0M | $276.6M |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Total Liabilities | $783.8M | $920.0M | $1.18B | $1.25B | $1.21B | $1.22B | $1.13B | $593.2M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $8.56B | $7.22B | $6.03B | $5.04B | $4.32B | $3.84B | $3.33B | $3.43B |
| Total Stockholders' Equity | $7.10B | $6.44B | $5.98B | $4.80B | $3.96B | $3.40B | $2.78B | $2.79B |